To include your compound in the COVID-19 Resource Center, submit it here.

VCN: Anti-tumor Ad-vantages

VCN Biosciences' oncolytic virus penetrates tumor stroma to treat pancreatic cancer

Pancreatic cancer is highly resistant to drugs because about 80% of the tumor is stroma - normal fibrous and connective tissues that support cancer cell growth and invasion - that compounds cannot penetrate efficiently. To overcome this problem, VCN Biosciences S.L. is developing VCN-01, a genetically engineered adenovirus that selectively penetrates the tumor stroma and replicates in pancreatic tumor cells to kill them.

Pancreatic cancer is a large unmet medical need, with a five-year survival rate of less than 5%, according to the American Association for Cancer

Read the full 864 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers